Tristel plc (AIM: TSTL), the Cambridgeshire-based manufacturer of infection prevention products, has announced the posting of its 2026 Annual Report and Accounts alongside a Notice of Annual General Meeting scheduled for 10 December 2026. The company has also confirmed a board change, with Non-Executive Director Tom Jenkins set to step down at the conclusion of the AGM after nine years of service. Tristel intends to appoint a new independent Non-Executive Director in due course, a process investors will be watching closely.

Key Points

  • Tristel plc (AIM: TSTL) — global infection prevention company using proprietary chlorine dioxide (ClO2) chemistry
  • AGM to be held on Thursday, 10 December 2026 at 11.00am at Lynx Business Park, Snailwell, Newmarket, Cambridgeshire
  • Non-Executive Director Tom Jenkins will not stand for re-election, having completed nine years on the Board
  • Investors should watch for the appointment of a new independent Non-Executive Director, which the company says will follow in due course

Tristel's 2026 Annual Report Posted Ahead of December AGM at Snailwell Headquarters

Tristel has confirmed that its Annual Report and Accounts for the year ended 30 June 2026 and the formal AGM Notice have been posted to shareholders and made available for download via the investor section of the company's website. The AGM will be held at the company's registered offices at Unit 1b, Lynx Business Park, Fordham Road, Snailwell, Newmarket, Cambridgeshire CB8 7NY. Tristel has been listed on London Stock Exchange's AIM market since 2005 and operates globally with approximately 280 employees across 16 subsidiaries, selling into more than 40 countries.

Tom Jenkins to Leave Tristel Board After Nine Years as Non-Executive Director

The announcement confirms that Tom Jenkins, who has served as a Non-Executive Director for nine years, will not stand for re-election at the forthcoming AGM and will step down from the board at the conclusion of the meeting. The company states his departure follows the end of his tenure. The board expressed its thanks for his dedication, support, and contribution over that period. Tristel has indicated it intends to appoint a new independent Non-Executive Director in due course, though no timeline or candidate details were disclosed in the announcement.

Chlorine Dioxide Chemistry and Global Decontamination Market Underpin Tristel's Business Model

Tristel is positioned as a market leader in the manual decontamination of medical devices, supplying hospitals globally under the Tristel brand. The company's products are built around its proprietary chlorine dioxide (ClO2) chemistry, which also underpins its sporicidal surface disinfection range — marketed as a sustainable alternative to pre-wetted plastic wipes. Headquartered and manufactured in Snailwell near Cambridge, the company targets double-digit revenue growth annually and an adjusted EBITDA margin of at least 25%. The announcement states the business is profitable, carries no debt, and operates a progressive dividend policy.

Board Composition and Governance Transition Now in Focus for TSTL Investors

With a senior independent non-executive directorship set to become vacant at the 10 December AGM, governance-focused investors may be watching Tristel's board renewal process. The company has stated an intention to recruit a replacement, though no further detail on timing or the candidate search process was included in the announcement. Chief Executive Officer Chris Lee and Chief Financial Officer Anna Wasyl remain in post. The AGM and accompanying annual report will provide shareholders with the next formal opportunity to scrutinise the company's strategic and financial progress for the year ended 30 June 2026.